Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer

Xie, Chen; Subhash, Vinod Vijay; Datta, Arpita; Liem, Natalia; Tan, Shi Hui; Yeo, Mei Shi; Tan, Wei Ching; Koh, Vivien; Yan, Fui Leng; Wong, Foong Ying; Wong, Wai Keong; So, Jimmy Bok Yan; Tan, Iain Beehuat; Padmanabhan, Nisha; Yap, Celestial T.; Tan, Patrick; Goh, Liang Kee; Yong, Wei Peng

doi:10.1007/s13402-015-0261-5

Cited by 27 publications

(24 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…p53 is well-known for its role as the guardian of the genome. It also plays a pivotal role in suppressing tumorigenesis (43). Our experimental data demonstrate that two p53-dependent pathways play pivotal roles in this process, as shown in Fig.…”

Section: Discussionsupporting

confidence: 65%

Differences in telomerase activity and the effects of AZT in aneuploid and euploid cells in colon cancer

Xiao

Yin

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

Telomerase-targeted treatments for cancer have received a great deal of attention because telomerase is detected in nearly all cancer cells but is not expressed in most normal tissues. Aneuploidy refers to a chromosome number that is not a multiple of the base chromosome number and can indicate either hypo- or hyperploid chromosome numbers. Most solid tumors are aneuploid. In the present study, we sought to determine whether there are differences in telomerase activity and hTERT gene expression between aneuploid and euploid cells. Furthermore, we investigated telomerase inhibitor 3'-azido-3'-deoxythymidine (AZT)-induced cell apoptosis using the p53-Puma/Noxa/Bax pathway and cell cycle arrest using the p53-p21 pathway in both aneuploid and euploid cells. Our results demonstrate that telomerase activity and hTERT gene expression were higher in aneuploid than in euploid cells. In addition, AZT exerted time- and dose-dependent cytotoxic effects on both aneuploid and euploid cells, and aneuploid cells were more sensitive to AZT-induced cytotoxicity. In addition, both the p53-Puma/Noxa/Bax pathway and the cell cycle arrest-associated p53-p21 pathway were involved in the AZT-induced suppression of tumor cells. Importantly, aneuploid cells were more sensitive to AZT-induced cell cycle arrest (p53-p21) and DNA double-strand breaks (γ-H2AX), while euploid cells were more sensitive to AZT-induced apoptosis (p53-Puma/Bax/Noxa).

show abstract

Section: Discussionsupporting

confidence: 65%

Differences in telomerase activity and the effects of AZT in aneuploid and euploid cells in colon cancer

Xiao

Yin

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…In investigating this process, we focused on MAGE‐A3, a member of tumor‐testis antigens family. MAGE‐A3 is an emerging prognostic factor for GC and is likely a marker for the early diagnosis and micrometastasis identification of GC 21,22 . In this study, we also verified that MAGE‐A3 was closely related with poor prognosis of GC.…”

Section: Discussionsupporting

confidence: 77%

“…Melanoma‐associated antigen‐A3 is over‐expressed in many malignant tumors (eg, colorectal and liver cancer) and has a high degree of specificity, especially in GC, with the positive expression rate up to 40% 21 . The current researches on MAGE‐A3 indicate that MAGE‐A3 can promote tumor cell proliferation and affect tumor prognosis by regulating multiple apoptotic proteins 22 . Thus, we hypothesized that YAP/MAGE‐A3 may be a new target for sitagliptin.…”

Section: Introductionmentioning

confidence: 99%

Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma‐associated antigen‐A3 expression through Yes‐associated protein inactivation

Wang

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Sitagliptin is an emerging oral hypoglycemic agent that inhibits the development of a wide variety of tumors. Current researches indicate that the abnormal activation of Yes-associated protein (YAP) promotes the proliferation and poor prognosis of multiple tumors. However, the ability of sitagliptin to regulate YAP and its effects on gastric cancer (GC) cells remain unclear. Here, we first showed that sitagliptin inhibited the proliferation of GC cells, and this inhibition was regulated by Hippo pathway. Sitagliptin phosphorylated YAP in a large tumor suppressor homolog-dependent manner, thereby inhibiting YAP nuclear translocation, and promoted YAP cytoplasm retention. This inhibition can be blocked by adenosine 5′-monophosphate-activated protein kinase (AMPK). Moreover, sitagliptin could reduce the expression of tumor-testis antigen Melanoma-associated antigen-A3 through YAP. In conclusion, sitagliptin may have a potential inhibitory effect on GC by AMPK/YAP/ melanoma-associated antigen-A3 pathway. K E Y W O R D Sgastric cancer, MAGE-A3, sitagliptin, YAP

show abstract

“…12,13 The expression of several MAGE subgroups is correlated with poor prognosis and chemotherapeutic resistance. 14 It was reported that MAGE-A11 is an independent poor prognostic marker for esophageal squamous cell carcinoma (ESCC). 15 And frequently expressed in breast cancer which is associated with poor prognosis as well.…”

Section: Introductionmentioning

confidence: 99%

<p>MAGE-A11 Expression Predicts Patient Prognosis in Head and Neck Squamous Cell Carcinoma</p>

Jia

Zhang

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancer worldwide. Growing evidence showed that Melanoma-associated antigen-A11 (MAGE-A11) was abnormally expressed in various malignancies, but MAGE-A11 expression and its biological roles in HNSCC had not been reported in detail. The aim of the study was to investigate the association between MAGE-A11 signatures and clinicopathological features of HNSCC patients and uncover its potential mechanisms in HNSCC patients. Methods: In the present study, we analyzed the expression of MAGE-A11 gene and evaluated the impact of MAGE-A11 genes expression on clinical outcome from the Cancer Genome Atlas (TCGA) database. MAGE-A11 expression was assessed in a wellcharacterized series of HNSCC (N = 75) with long-term follow-up and 10 cases of adjacent non-cancerous tissues, which were diagnosed between 2013 and 2014, by using immunohistochemistry. The correlation between MAGE-A11 expression and clinicopathological factors was analyzed. Kaplan-Meier and Cox regression analyses were used to assess the prognostic significance of MAGE-A11 expression among HNSCC patients. Results: The results showed that MAGE-A11 mRNA expression was increased in HNSCC tissues compared to "normal" tissues (P < 10 −12). MAGE-A11 protein expression was not correlated with lymph node status, relapse, age, gender, histological grade, differentiation, clinical stage, tumor size, radiotherapy or chemotherapy. The patients with high MAGE-A11 expression had lower 5-year overall survival (OS) rates than those with low MAGE-A11 expression as determined using the Kaplan-Meier method. The univariate and multivariate analyses confirmed that elevated MAGE-A11 was an independent prognostic factor for the OS of HNSCC patients. Conclusion: These findings indicate that MAGE-A11 may be a valuable diagnostic or prognostic marker as well as a potential molecular therapy target for HNSCC patients.

show abstract

Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer

Cited by 27 publications

References 48 publications

Differences in telomerase activity and the effects of AZT in aneuploid and euploid cells in colon cancer

Differences in telomerase activity and the effects of AZT in aneuploid and euploid cells in colon cancer

Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma‐associated antigen‐A3 expression through Yes‐associated protein inactivation

<p>MAGE-A11 Expression Predicts Patient Prognosis in Head and Neck Squamous Cell Carcinoma</p>

Contact Info

Product

Resources

About